1. Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome 
Scott R. Solomon, Bipin N. Savani, Richard Childs, Aldemar Montero, Carol Boss, Elizabeth J. Read, Susan F. Leitman, A. John Barrett 
Biology of Blood and Marrow Transplantation 
Volume 11, Issue 8, Pages (August 2005)
DOI: /j.bbmt
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Effect of disease type on transplantation outcomes. A, Overall survival (OS). B, Relapse-free survival (RFS). C, Relapse. Disease types include RA/RAEB (n = 15), refractory anemia with excess blasts in transformation (RAEB-t)/secondary AML [sAML] (n = 19), and treatment-related MDS (n = 9).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Effect of GVHD on relapse after transplantation. Relapse risk is shown by the presence (n = 27) or absence (n = 16) of graft-versus-host disease (acute and/or chronic).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Transplantation outcomes in patients younger than 50 years of age who underwent standard TBI-based conditioning. A, Overall survival (OS). B, Relapse-free survival (RFS). C, Transplant-related mortality (TRM). D, Relapse.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Effect of age on transplantation outcomes in primary MDS. Transplant-related mortality is shown by age: <50 years (n = 19) or ≥50 years (n = 15).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions